Abstract:Mit Alogliptin ist ein weiterer DPP-4-Hemmer in der Schweiz eingeführt worden. Die Substanz führt zwar zu einer mässigen Senkung des HbA1c, konnte aber die Inzidenz kardiovaskulärer Komplikationen nach einem akuten koronaren Ereignis nicht vorteilhaft beeinflussen.
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.